Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GPR139 | Q6DWJ6 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL878124 | 0.92 | GPR139 (0.44) | HTTKMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL15732962 | 0.89 | GPR139 (0.49) | HTTKMT2AALDH1A1LMNAHSD17B10 | |
| SCHEMBL877403 | 0.83 | MMP2 (0.53) | HTTKMT2AALDH1A1MEN1HSD17B10 | |
| SCHEMBL875423 | 0.83 | GPR139 (0.45) | HTTKMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL878096 | 0.83 | GPR139 (0.45) | HTTKMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL875589 | 0.82 | GPR139 (0.49) | HTTALDH1A1LMNAHSD17B10GPR139 | |
| SCHEMBL874668 | 0.81 | GPR139 (0.49) | KMT2ALMNAGPR139MAPTSMN1; SMN2 | |
| SCHEMBL874885 | 0.80 | GPR139 (0.48) | HTTKMT2AMEN1GPR139SMN1; SMN2 | |
| SCHEMBL877231 | 0.80 | GPR139 (0.47) | HTTKMT2AALDH1A1LMNAGPR139 | |
| SCHEMBL874661 | 0.79 | CTNNB1 (0.44) | HTTKMT2AMEN1GPR139SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP12, MMP10 | HTT 4338/4885KMT2A 3501/4885ALDH1A1 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.